Tesla
TSLA
MicroStrategy
MSTR
MARA Holdings
MARA
Apple
AAPL
Microsoft
MSFT
US Stock MarketDetailed Quotes
VRDN Viridian Therapeutics
- 17.850
- -0.140-0.78%
Close Dec 13 16:00 ET
- 20.000
- +2.150+12.04%
Post 20:01 ET
1.41BMarket Cap-4.13P/E (TTM)
17.990High17.250Low1.56MVolume17.830Open17.990Pre Close27.46MTurnover1.97%Turnover RatioLossP/E (Static)79.21MShares27.20052wk High2.73P/B1.41BFloat Cap11.40052wk Low--Dividend TTM79.15MShs Float2247.750Historical High--Div YieldTTM4.11%Amplitude4.665Historical Low17.615Avg Price1Lot Size
About Viridian Therapeutics Company
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
Company Profile
SymbolVRDN
Company NameViridian Therapeutics
Listing DateJun 18, 2014
Issue Price10.00
Founded2006
CEOMr. Stephen Mahoney
MarketNASDAQ
Employees94
Fiscal Year Ends12-31
Address221 Crescent Street,Suite 401
CityWaltham
ProvinceMassachusetts
CountryUnited States of America
Zip Code02453
Phone1-617-272-4600
Company Executives
- Name
- Position
- Salary
- Stephen Mahoney
- President, Chief Executive Officer and Director
- 12.48M
- Jennifer Tousignant
- Chief Legal Officer
- --
- Thomas W. Beetham
- Chief Operating Officer
- 4.76M
- Dr. Thomas Ciulla
- Chief Medical Officer
- --
- Seth Harmon
- Senior Vice President, Finance and Accounting, Principal Accounting Officer and Principal Financial Officer
- 6.55M
- Tomas Kiselak
- Chairman of the Board
- 503.83K
- Dr. Sarah Gheuens
- Independent Director
- 482.53K
- Arlene M. Morris
- Independent Director
- 477.83K
- Peter Harwin
- Independent Director
- 471.83K
- Jennifer K. Moses
- Independent Director
- 467.83K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.